Research Methodology Used for This Study:
Top-down and bottom-up approaches were used to validate the size of the global cell viability assays market and estimate the size of other dependent sub markets. Various secondary sources such as directories; industry journals; databases such as D&B Hoovers, Bloomberg Business, and Factiva; and annual reports of companies have been used to identify and collect information useful for the study of this market. Primary sources such as experts from both the supply and demand sides have been interviewed to obtain and validate information as well as to assess the dynamics of this market.
# Manufacturers of cell viability instruments and consumables
# Distributors of cell viability instruments and consumables
# Research and development organizations
# Hospitals and clinics
# Diagnostic centers
# Market research and consulting firms
# Venture capitalists and investors
The cell viability assays market is expected to reach USD 4.16 billion by 2023 from an estimated USD 2.78 billion in 2018, at a CAGR of 8.4%.
The major factors driving the growth of this market include the rising incidence and prevalence of chronic and infectious diseases, growing availability of funds for research, rising demand for cell-based assays in research, and increasing focus on the development of cell-based therapeutics.
Download PDF Brochure@
By application, the drug discovery & development application segment is estimated to hold the largest share in 2018
Based on application, the cell viability assays market is segmented into drug discovery & development, basic research, stem cell research, clinical & diagnostic applications, and other applications. In 2018, the drug discovery & development application segment is expected to account for the largest share of the global cell viability assays market. The large share of this segment can be attributed to the rising incidence and prevalence of chronic and infectious diseases and increasing government support for developing new treatments for various human diseases.
Objectives of the Study:
# To define, describe, segment, and forecast the global cell viability assays market by product, application, cell type, end user, and region.
# To provide detailed information about the factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges).
# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.
# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
# To forecast the size of the cell viability assays market in five main regions (along with major countries) North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
# To profile key players in the global cell viability assays market and comprehensively analyze their core competencies and market shares.
# To track and analyze competitive developments such as mergers and acquisitions; new product/technology launches; expansions; collaborations and agreements; and R&D activities of the leading players in the global cell viability assays industry.
By end user, the pharmaceutical and biotechnology companies segment is estimated to hold the largest share of the cell viability assays market in 2018
On the basis of end user, the cell viability assays market is segmented into pharmaceutical and biotechnology companies, hospital and diagnostic laboratories, academic and research institutes, and other end users (food and beverage companies and environmental testing companies). The pharmaceutical and biotechnology companies segment is expected to account for the largest share in 2018. The large share of this segment can be attributed to the increasing number of R&D activities undertaken by these companies for the development of biopharmaceutical products.
Major Growth Restraint:
# High Cost of Instruments
# Emerging Markets
# Growing Focus on Stem Cell Research
North America to dominate the market in 2018
North America is expected to account for the largest share of the cell viability assays market in 2018, followed by Europe and Asia Pacific. The growing incidence rate of various infectious diseases, investment initiatives by the government, and the high-quality infrastructure for clinical and laboratory research are the major factors responsible for the large share of the North American cell viability assays market. Moreover, a number of major global players are based in the US, owing to which, the US is a center for innovation in the cell viability assays market.
Request Sample Pages@
Global Industry Leaders:
Players in the global cell viability assays market, such as Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Merck (Germany), GE Healthcare (US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), G-Biosciences (US), Creative Bioarray (US), Danaher Corporation (US), and Becton, Dickinson and Company (US).
These leaders are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies of product launches, expansions, agreements, collaborations, and acquisitions.